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Venous ulceration is the final outcome of lower
extremity chronic venous insufficiency in most cases.
It is a debilitating recurrent complication with an
estimated prevalence rate of 0.1% to 0.2% of the
population in developed countries.1 The pathophys-
iologic mechanisms at the microcirculatory levels are
still not well understood.
In previous experiments in our laboratory, we
demonstrated that the fibroblasts that were cultured
from venous ulcers exhibited reduced growth rates
and were morphologically different (larger in size)
when compared with the normal fibroblasts that
were isolated from the ipsilateral limb of the same
patient.2 We further demonstrated that the wound
fibroblasts in vitro displayed more characteristics of
senescence, such as increased senescence associated
b -galactosidase activity (SA-b –Gal) and an increased
level of fibronectin production,3 which are both
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Purpose: Venous reflux precedes the development of venous ulcers. Our earlier work
showed that the fibroblasts that are cultured from these wounds display more charac-
teristics of senescence. We evaluated fibroblast senescence in patients with venous reflux
but without ulcers to further investigate the role of venous reflux in the predisposition
to venous ulcers.
Methods: Fibroblasts that were isolated from skin biopsy specimens of the “gaiter” area
(distal) and of the ipsilateral thigh of the same patient (proximal) were compared.
Twelve patients with venous reflux (9 patients in clinical, etiologic, anatomic, and patho-
logic classification 4; 3 patients in classification 5) with an average venous filling index
of 5.45 mL/s and 4 patients without venous reflux were enrolled in the study. The
growth rates, the response to basic fibroblast growth factor (b-FGF), and the senescence
markers (b -galactosidase activity at a pH level of 6, unstimulated fibroblasts fibronectin
protein, and messenger RNA levels) were determined for each cell population.
Results: The number of senescence-associated b -galactosidase positive cells (8.3% ± 1.9%
vs 2.2% ± 0.8%; P = .008) and the level of cellular fibronectin protein (455.7 ± 80 vs 210
± 51; P = .04) and messenger RNA (16.8 ± 6.8 vs 13.5 ± 5.7; P = .042) were significantly
higher in the distal fibroblasts as compared with the proximal fibroblast cultures. The
growth rates of the distal fibroblasts were lower when compared with the proximal
fibroblasts (15,746 ± 4287 cells/day vs 29,550 ± 5035 cells/day; P < .002) but were not
different in the presence of b-FGF (41,717 ± 9542 cells/day vs 47,030 ± 6133 cells/day;
P = .53). In the patients without venous reflux, no site differences were noted in the
growth rates or the senescence markers between the proximal and distal fibroblasts.
Conclusion: Distal fibroblasts that are isolated from patients with venous reflux display
more senescence characteristics than do proximal fibroblasts and have significantly lower
growth rates. Despite senescence, b-FGF restored the distal-fibroblasts growth rate to
that of the stimulated proximal fibroblasts, which proposes a therapeutic role for b-FGF.
These changes precede ulcer formation and suggest a mechanism that is focal and intrin-
sically related to venous reflux. (J Vasc Surg 1998;28:1040-50.)
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well-described characteristics of the human senes-
cent fibroblast.4,5
The accumulation of the senescent fibroblasts
within the ulcer environment could affect the heal-
ing process through several mechanisms, such as the
overexpression of proteolytic activity (an increase in
the production of matrix metalloproteinases and the
underexpression of protease inhibitors), dermis
immunomodulation (the overexpression of inter-
leukin-1,7 and the underexpression of interleukin-6
and interleukin-8 after TNF-a challenge)8, and an
altered matrix deposition (the increased production
of abnormal fibronectin)9.
It is not known whether the fibroblast abnor-
malities that are found in venous ulcers are a preex-
isting local phenomena induced by intrinsic mecha-
nisms, such as chronic venous hypertension, or
whether these changes are induced by the extrinsic
mechanisms associated with the ulcer environment,
such as injury, bacterial colonization, or infection.
We hypothesized that chronic venous hyperten-
sion through intrinsic mechanisms, such as the
sequestration and activation of macrophages or mast
cells within the dermal compartment, affect the
fibroblast function and lead to a relative accumula-
tion of senescent fibroblasts before ulcer formation.
This study was designed to examine whether
fibroblasts that were isolated from the dermis of the
distal lower extremities of patients with venous
reflux but no ulcers display abnormalities similar to
those that are found in the ulcer fibroblasts.
METHODS
Patients. The patients with symptomatic venous
disease were interviewed and examined. The evalua-
tion of the venous disease was performed clinically by
a trained vascular surgeon with the guidelines that
were prepared by the Executive Committee of the
American Venous Forum (Clinical Classification and
Grading of Chronic Venous Disease),10 and venous
reflux was determined in the noninvasive vascular
laboratory by means of air plethysmography and
venous duplex scan examinations. The patients in
whom concomitant arterial disease was suspected
because of absent pulses were excluded from the
study. The patients who were taking immunosuppre-
sive medication also were excluded from the study.
All the patients with diabetes and the patients with
known HIV-positive status were excluded as well.
The Institutional Review Board at Boston Medical
Center approved this study, and informed consent
was obtained for all patients who were enrolled in the
study. In addition, the healthy volunteers without
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venous disease were interviewed and examined and
underwent noninvasive vascular examination for
assessment of asymptomatic venous reflux.
Assessment of venous reflux. All the patients
underwent noninvasive vascular testing at the Boston
Medical Center Vascular Laboratory. A venous filling
index, as determined by means of air plethysmogra-
phy, that was greater than 2 mL/s was used as the
criteria for the diagnosis of venous reflux. Venous
duplex scan evidence of significant venous retrograde
flow or of anatomical valvular incompetence of the
superficial, deep, or perforating venous system also
was considered as inclusion criteria.
Materials. Dulbecco’s modified Eagle’s medium,
trypsin, and Trizol reagents were purchased from
GibcoBRL Life Technologies, Inc (Gaithersburg, Md).
The monoclonal anticellular fibronectin antibody was
purchased from Sigma (St Louis, Mo). The recombi-
nant human basic fibroblast growth factor (b-FGF) 
was obtained from Collaborative Research. The 
ECL Western blotting detection system kit was pur-
chased from Amersham Life Science (Arlington
Heights, Ill). The bovine calf serum was obtained from
Hyclone Laboratories, Inc (Logan, Utah). The nitro-
cellulose and nylon membranes were purchased from
Amersham (Arlington Heights, Ill), and the oligolabel-
ing kit was from Pharmacia LKB Biotechnology
(Piscataway, NJ). The radiolabeled nucleotide, d-CTP,
was from New England Nuclear (Boston, Mass), and
the X-Gal (5-bromo-4-chloro-3-indolyl b -D-galacto-
side) was purchased from Sigma.
Fibroblast isolation and culture. From each
patient or volunteer, a biopsy was obtained from the
uninvolved skin of the proximal thigh and from the
uninvolved skin of the “gaiter” area of the ipsilateral
limb. The techniques that were used to isolate and cul-
ture the dermal fibroblast are described in detail else-
where.2 In brief, the biopsies were treated with a 5-
minute povidone-iodine bath that was followed by a 5-
minute bath in a 70% ethanol solution. An overnight
trypsin incubation then was performed at 4°C (trypsin
solution, 1 m g/mL), which allowed for the separation
of the dermal tissue from the epidermal and adipose
tissue. The dermal tissue was isolated with sterile con-
ditions, cut sharply into 1-mm to 2-mm fragments,
and placed in etched plastic tissue culture dishes
(Fisher, Pittsburgh, Pa). A complete medium that con-
sisted of Dulbecco’s modified Eagle’s medium with
10% calf serum and antibiotic solution (penicillin,
methicillin, fungizone, and streptomycin) was added
to support cell growth. Two separate fibroblast popu-
lations were obtained from each patient or subject—
the proximal fibroblasts and the distal fibroblasts. The
Fibronectin protein analysis (immunoblot).
An immunoblot analysis (Western blot) for cellular
fibronectin was performed after the extraction of the
matrix proteins from the fibroblast culture dishes.
The second passage fibroblasts were allowed to
achieve an 89% to 90% confluence in 60-mm culture
dishes. The urea-based extraction of the matrix pro-
teins then was performed by lysing the cells into a 4-
mol/L urea buffer and homogenate set for 1 to 2
hours at 4°C. The total amount of protein was quan-
tified with the Bradford protein assay technique,
which is described elsewhere. Ten to 30 m g of cell
lysate protein was separated with a 7.5% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis.
The same amount of total urea extracted protein was
loaded for both the proximal fibroblasts and the dis-
tal fibroblasts cultures from each patient. The pro-
teins then were transferred from the gel to a nitro-
cellulose membrane. The membrane was preincu-
bated in 100% Blotto (5 g of nonfat dry milk in 100
mL of PBS) with shaking for 1 hour at room tem-
perature. This was followed by the incubation with a
mouse antihuman monoclonal antibody against cel-
lular fibronectin (0.2 to 1 m g/mL in 10% Blotto) at
4°C. At the end of the incubation, the membrane
was washed extensively with PBS, which contained
0.5% Tween-20, and then was reacted with the sec-
ondary goat antimouse antibody labeled with horse-
radish peroxidase. Chemiluminescent reaction with
ECL Western blotting analysis system was used to
detect the fibronectin bands with autoradiography
exposing membrane to Kodak X-Omat film.
Fibronectin mRNA detection. The total RNA
was extracted from the passage 3 fibroblasts at an
80% to 90% confluence in 60-mm culture dishes by
lysing the cells with the Trizol reagent (1 mL per 60-
mm dish). The lysate was equilibrated at room tem-
perature for 5 minutes and was extracted with chlo-
roform (0.2 mL per 1 mL of Trizol reagent). The
RNA was precipitated by adding 0.5 mL of iso-
propyl alcohol per 1 mL of Trizol reagent. Equal
amounts (7 to 10 m g) of total cellular RNA from the
proximal fibroblasts and the distal fibroblasts of the
same patient were separated electrophoretically
through a 1% agarose gel that contained 2.2 mol/L
formaldehyde, were blotted on a Hybond-N nylon
membrane, and were immobilized with short ultra-
violet light illumination. The blot was prehybridized
for 24 hours and incubated with the specific radiola-
beled fibronectin insert (2.0 · 106 to 3.0 · 106
cpm/mL hybridization solution) for 24 hours. The
membrane were washed twice for 30 minutes with
2· standard saline citrate solution at 65°C and then
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cells then were passed into 2 separate tissue culture
dishes (passage 1). Once an 80% to 90% confluence
was reached, one plate was used to freeze the fibrob-
lasts with dimethyl sulfoxide solution, and then the
cells were stored at –140°C in liquid nitrogen until
further testing. From the second plate, the fibroblasts
were harvested and used for analyses (passage 2). The
passage 3 fibroblasts were used for RNA harvesting
and Northern Blot analysis.
Growth curves. The growth curves were
assessed by plating 1500 passage 2 fibroblasts from
each cell population in 35-mm culture dishes and by
determining the total cell number per plate with a
Coulter counter on days 7, 10, 13, and 16. The plot-
ting of the total cell number against the harvesting
days generated the growth curves. The growth rate
was determined with the slope of a best-fit line that
was calculated with regression analysis for each
growth curve. In addition, the doubling times (DT)
were calculated for each cell population. The effect of
b-FGF on the growth rates also was assessed for both
the proximal fibroblasts and the distal fibroblasts at a
final concentration of 100 ng/mL. This concentra-
tion was found to have the maximum response test-
ed in the previous experiments in our laboratory.2
Assessment of senescence markers in vitro.
The fibroblasts were further divided into 3 groups:
(1) the fibroblasts that were used for the determina-
tion of SA-b –Gal activity (passage 2 fibroblasts), (2)
the fibroblasts that were used for the extracellular
matrix protein extraction and the determination of
fibronectin protein (passage 2 fibroblasts), and (3) the
fibroblasts that were used for the extraction of total
RNA and the determination of the fibronectin mes-
senger RNA (mRNA) content (passage 3 fibroblasts). 
Senescence-associated b -galactosidase activity.
The SA-b –Gal staining was performed according to a
protocol that was described previously. Briefly, after
being fixed with a 2% formaldehyde/0.2% glutaralde-
hyde solution in phosphate-buffered saline solution
(PBS), the second passage fibroblast cultures at 30% to
50% confluence were incubated with the staining solu-
tion (20 mg/mL X-Gal in dimethylformamide; 0.2
mol/L citric acid; sodium phosphate buffer, pH = 6.0;
100 mmol/L potassium ferrocyanide; 100 mmol/L
potasium ferricyanide; 5 mol/L sodium chloride; 1
mol/L magnesium chloride; and H2O). The plates
were incubated for 12 to 16 hours at 37°C without
CO2. The positive cells characteristically display a per-
inuclear precipitation of blue dye. This allows for a clear
identification with standard light microscopy. The per-
centage of positive SA-b –Gal cells is determined after a
count of a total of 300 to 400 cells per culture dish. 
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exposed to Kodak XAR-5 film. The 28S and the 18S
ribosomal RNA subunits that were obtained from
the ethidium bromide gels were used as controls to
normalize the fibronectin mRNA that was detected
for each cell population.
Fibronectin probe. The complementary DNA
that was specific for fibronectin was purchased from
the American Type Cell Culture (Kockville, Md).
The complementary DNA was radiolabeled with
[32P]-d-CTP (specific activity, 370 MBq/mL) with
a commercial oligolabeling kit.
Assessment of senescence markers in vivo. The
immunohistochemistry analysis of the fibronectin
deposition was performed in frozen sections that were
obtained from the skin biopsies procured from the
proximal and the ipsilateral distal lower extremities
(gaiter area) of the patients with venous reflux. The
specimens rapidly were frozen and embedded in the
optimal cutting temperature. Thin sections (8 m m)
were cut, mounted onto glass slides, and frozen at
–70°C until processing. The glass slides then were
thawed and washed for 5 minutes with PBS, and the
sections were fixed for 10 minutes in 5% formalin, 2
mmol/L ethyleneglycol-bis-( b -aminoethylether)-
N,N,N’,N’-tetraacetic acid, and 2 mmol/L MgCl2.
The slides were incubated at 37°C in the pre-
sence of goat serum to reduce nonspecific binding.
Subsequently, the slides were incubated with a mouse
antihuman cellular fibronectin monoclonal antibody
(Sigma) followed by a fluorescein-conjugated rabbit
antimouse policlonal antibody (Sigma). A confocal flu-
orescent microscope (Leica, Leica Technology, BV
Rijswijk, The Netherlands) was used to visualize the
fibronectin deposition within the dermis of each sec-
tion. Laser voltage (990 V) was maintained constant
for each slide, and a 25· objective (0.75 numerical
aperture) was used. The images were analyzed with
image analysis software (Image Tools, The University
of Texas Health Science Center, San Antonio).
Assessment of biopsy site differences in
fibroblast function. The fibroblasts were isolated
from the patients and the volunteers without venous
reflux were studied to evaluate whether the site of
the biopsy may influence the fibroblast growth rates
and senescence. The growth rates, the responses to
b-FGF, and the SA-b –Gal activity were determined
for these fibroblasts. 
Statistical analyses. A paired Student t test was
used to compare the growth rates, the SA- b –Gal
activity, and the density of the fibronectin bands from
immunoblot analysis. The Mann-Whitney rank sum
test was used to analyze the fibroblasts DT data and
the integrated optical densities that were obtained
from the autoradiographs of the Northern blot
analysis. A linear regression model was used to esti-
mate the growth rate from each growth curve. The
image analysis software (Image Tools) was used to
calculate the relative integrated optical densities from
the scans of immunoblots and Northern blot analy-
ses and to calculate the fluorescent intensity that was
obtained from the confocal microscopic images.
RESULTS
A total of 23 patients with symptomatic venous
disease were enrolled in this study. At the vascular
noninvasive testing, 18 patients with venous reflux
and 5 patients without venous reflux were identified.
Of the original 18 patients with reflux, 12 complet-
ed all the stages of the study as did 4 of the 5
patients without reflux. All of the patients with
venous reflux fell into the symptomatic clinical clas-
sification categories 4 and 5, according to the
American Venous Forum ad hoc committee consen-
sus statement from 1994.10 Only 3 of these patients
fell into category 5. The mean venous filling index
for the group with venous reflux and the group
without venous reflux were 5.45 ± 1.5 mL/s and 1
± 0.2 mL/s, respectively. Of the 12 patients with
venous reflux, 4 were men and 8 were women. The
mean age of the group was 48.5 years (range, 29 to
74 years). No patients had a documented history of
deep venous thrombosis or major lower extremity
trauma. The associated comorbidity was only hyper-
tension in 2 patients.
Fibroblast growth rates in patients with
venous reflux. For the patients with venous reflux,
Table I. Fibroblast growth rates in patients with venous reflux (n = 12)
Growth rates (cells/day) P value
Fibroblast population No b-FGF b-FGF (100 ng/mL)
Proximal fibroblasts 29,550 ± 5035 47,030 ± 6133 .012
Distal fibroblasts 15,746 ± 4287 41,717 ± 9542 .016
P value .016 .53
b-FGF, Basic fibroblast growth factor.
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the distal fibroblast growth rates were significantly
lower than the proximal fibroblast growth rates in 9
of the 12 patients. The mean growth rate for the
proximal fibroblasts was 29,550 ± 5035 cells/day
versus 15,746 ± 4287 cells/day for the distal fibro-
blasts. A comparison of the proximal fibroblast and
the distal fibroblast growth rates with a 2-tailed
paired t test showed a statistically significant differ-
ence (P = .016; Table I). The median DT of the
proximal fibroblasts was 43.9 hours versus 66.2
hours for the distal fibroblasts (P = .001; Table II).
Senescence-associated b -galactosidase activity.
SA-b –Gal activity was detected in 8 of the 12 proxi-
mal fibroblast cultures, with a mean of 2.2% ± 0.8%
of the cells staining positive. In the distal fibroblast
populations, SA- b –Gal activity was detected in 12 of
the 12 patients, with a mean of 8.32% ± 1.9%. A
comparison of the proximal fibroblast versus the dis-
tal fibroblast SA- b –Gal activity with a 2-tailed paired
t test showed a statistically significant difference (P =
.0084; Table III). No significant correlation between
the percentage differences of SA- b –Gal positive cells
and the differences in the growth rates between the
proximal fibroblasts and the distal fibroblasts was
found (data not shown). 
Fibronectin protein level and mRNA expres-
sion. When comparing the Northern blot analysis
bands, the integrated densities were normalized with
the corresponding density of the 18S ribosomal RNA
subunit for each band to account for the differences
in loading. The distal fibroblast fibronectin mRNA
was upregulated in 7 of the 10 patients who were test-
ed with a mean normalized integrated density of
18.03 ± 4.46 versus 14.3 ± 6.2 of the proximal
fibroblasts (P = .013; Fig 1). The distal fibroblast
fibronectin protein level was higher in 8 of the 10
patients when compared with the corresponding
proximal fibroblast cultures with a mean integrated
Fig 1. Fibronectin messenger RNA, as determined with Northern blot analyses, from 80% to
90% confluent proximal fibroblast (P) and distal fibroblast (D) cultures of patients with venous
reflux but no ulcers. Proximal fibroblasts and distal fibroblasts were cultured at same time with
same culture conditions for each patient before harvest of total RNA. Integrated densities (ID)
were calculated from scans of autoradiographs with an image analysis software. Also, ultravio-
let light photographs were made of the ethidium bromide gels that showed the 28S and 18S
ribosomal RNA subunits. Normalized integrated densities (NID) were obtained with the inte-
grated densities of the 18S ribosomal RNA subunit. Fibronectin messenger RNA was upregu-
lated in 7 of 10 patients (P = .013).
Fig 2. Fibronectin protein level, as determined by immunoblot technique, from 80% to 90%
confluent proximal fibroblast (P) and distal fibroblast (D) cultures of patients with venous
reflux but no ulcers. Both cell populations were cultured simultaneously under same culture
conditions for each patient before urea extraction of matrix proteins. An equal amount of total
protein from proximal and distal fibroblasts was loaded into each lane of sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis. Integrated densities (ID) were calculated from scans
of autoradiographs with an image analysis software. Fibronectin protein level was upregulated
in 8 of 10 patients (P = .04).
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density of 455.7 ± 80 versus 210 ± 52 (P = .04; Fig
2). Six of those 8 patients with increased fibronectin
protein also had increased levels of fibronectin mRNA
on Northern blot analysis. 
Dermal fibronectin in-vivo (frozen sections).
The results of the immunohistochemistry examination
for fibronectin deposition in the frozen sections are
shown in Fig 3. When comparing the proximal dermis
with the distal dermis, a clear increase in the level of
dermal fibronectin deposition was evident in 3 of the
6 patients who were tested. This was confirmed by the
measurement of the relative fluorescence intensity with
the image analysis software. When the proximal skin
fluorescent intensity was compared with that of the
distal skin with paired t test analysis, no significant dif-
ference was noted (P = .87; Table IV).
Effects of b-FGF on growth rates. b-FGF was
mitogenic to both the proximal and the distal fibro-
blasts (P < .02). The growth rates for the proximal
fibroblasts and the distal fibroblasts in the presence of
b-FGF were not significantly different (47,030 ±
6133 cells/day vs 41,717 ± 9542 cells/day; P = .53;
Table I). The mean percentage increase in growth
rate for the proximal fibroblasts was 35.3% ± 10.6%
and for the distal fibroblasts was 45.8% ± 15.2%. This
difference was not statistically significant (P = .34).
When the data were analyzed by calculating the
fibroblast DT, b-FGF significantly reduced the pop-
ulation DT for both fibroblast populations, but the
distal fibroblast DT remained significantly longer
than that of the proximal fibroblasts (Table II). 
Fibroblast growth rates in patients without
venous reflux. In the subjects without venous
reflux, the proximal fibroblast and the distal fibro-
blast growth rates, in the presence or absence of b-
FGF, were not significantly different (Table V). The
nonstimulated median DTs were 43.9 hours and
41.6 hours, respectively (P = .87; Table II). The
mean percentage of SA-b –Gal positive cells for the
proximal fibroblasts was 1.4% ± 1.05% and for the
distal fibroblasts was 1.7% ± 1.2% (Table III). 
Table II. Median doubling times expressed in hours for each fibroblast population
Patients with venous reflux Patients without venous reflux
median fibroblast DT (hours) median fibroblast DT (hours)
No b-FGF b-FGF (100 ng/mL) P value No b-FGF b-FGF (100 ng/mL) P value
Proximal fibroblasts 43.9 35.7 .001 43.8 39.4 .25
Distal fibroblasts 66.2 46.7 .001 41.6 31.6 .25
P value .001 .01 .8 .7
Data were compared with nonparametric Mann-Whitney test. On average, the population doubling time of unstimulated distal fibro-
blasts exposed to venous hypertension was 2.23-fold longer than proximal fibroblasts.
DT, Doubling time; b-FGF, basic fibroblast growth factor.
Table III. Percentage of senescence-associated b -
galactosidase activity positive fibroblasts in vitro
from patients with venous reflux and patients with-
out venous reflux
Patients with venous Patients without
Fibroblast population reflux (n = 12) venous reflux (n = 4)
Proximal fibroblasts 2.2 ± 0.8 1.4 ± 1
Distal fibroblasts 8.3 ± 1.9 1.7 ± 1.2
P value .008 .23
The total number of cells counted by means of light microscopy
from each cell population was 300 to 400 cells. Subconfluent
(40% to 50%) second-passage fibroblasts were used in all patients.
Table IV. Dermal fibronectin protein deposition
in biopsies obtained from proximal thigh (proxi-
mal) and ipsilateral gaiter area (distal) in 6 patients
with venous reflux
Relative fluorescence intensity
Proximal Distal
72.6 43.16
31.76 98.36
127.95 55.91
156.24 228.88
73.48 119.24
162.7 104.84
Average
104.1 108.3
Fibronectin relative fluorescence intensity was determined from
immunohistochemical images obtained with a confocal micro-
scope with an image analysis software. 25· magnification and a
laser voltage of 990 V were kept constant for each slide. Data are
expressed in fluoroscent units and derived from comparisons of
total fluorescent intensity to a standard curve scanned and used
for calibration. No significant difference was observed when the
data were analyzed with paired t test (P = .87).
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DISCUSSION
For years, venous stasis ulceration and poor tissue
integrity have been associated with the hydrostatic
transmission of deep venous pressure to the fragile,
small superficial venous tributaries of the gaiter area.
This transmission of pressure occurs in the face of
incompetent valve leaflets whether they are in the
superficial, deep, or perforating systems.11-13
Numerous pathophysiologic mechanisms have
been proposed to explain the formation of the
venous ulcers and the nonhealing state that occurs in
limbs that are affected by chronic venous insuffi-
ciency. The trapping and activation of white blood
cells,14,15 the effect of the histopathologic findings
of fibrin cuffing,16 and the poor delivery of growth
factors17 have all been explanations that were cham-
pioned by various groups.
In our previous studies, the fibroblasts that were
isolated from the venous ulcers displayed reduced
growth rates and increased senescence characteris-
tics.2,3 The hallmark of cellular senescence is an irre-
versible arrest of cell proliferation with the mainte-
nance of metabolic activity with altered cell func-
tions. Cellular senescence depends on cumulative cell
divisions and not chronologic or metabolic age,
which indicates that proliferation is limited by a
“mitotic clock.”19,20 This mitotic clock recently has
been characterized to be the length of the chromo-
somal telomeres, and the extension of life-span has
been achieved through the elongation of the telom-
eres after the introduction of telomerase into normal
human fibroblasts.21 It was not clear in our previous
experience whether the increase of fibroblast senes-
cence was related to the intrinsic mechanisms within
the ulcer environment, such as venous hypertension,
or whether the increase was induced by extrinsic
mechanisms, such as injury, bacterial colonization, or
infection. In this study, we found that the fibroblasts
that were isolated from intact skin subjected to
venous hypertension have reduced growth rates, have
longer DT, and display more characteristics of cellu-
lar senescence than the fibroblasts that were isolated
from the skin not exposed to venous hypertension.
These data support the concept that (1) the fibrob-
last abnormalities that were found in the patients
with venous ulcers preexist in the patients who have
venous hypertension but no ulcers and are the result
of intrinsic mechanisms, and (2) the mechanisms that
are involved act at a local rather than systemic level.
b-FGF was mitogenic for both of the fibroblast
populations—proximal and distal. This is consistent
with our previous studies.2 Interestingly, b-FGF
restored the distal fibroblast growth rate to that of
the stimulated proximal fibroblasts. This is in con-
trast with our pervious experience in which the
growth rate of the fibroblasts that were isolated from
the venous ulcers was restored in most of the
patients to that of the unstimulated normal fibro-
blast,2 which implies a higher response rate by the
distal fibroblasts than by the ulcer fibroblasts.
The fibroblasts that migrate from the skin speci-
mens to the tissue culture dish by explant technique
are not senescent by definition because cell prolifer-
ation is a requisite. The fibroblast population that is
subsequently obtained is heterogeneous on the basis
of their in vivo cumulative cell divisions that range
from “young” fibroblasts (those that underwent
only a few cell divisions before biopsy) and senescent
fibroblasts (those that exhausted their proliferative
capacity). In between, there are fibroblasts at differ-
Fig 3. Representative images of immunohistochemically
(IH) localized fibronectin protein deposition within the
dermis of patient with venous reflux. Images were
obtained with confocal microscopy at 25· magnification.
In image 1 (negative control), mild nonspecific binding of
the secondary antibody was evident only in epidermis (e).
In image 2, fibronectin deposition is localized primarily in
the dermis (d) as expected. Images 3 and 4 show the level
of fibronectin deposition within the dermis of biopsies
obtained from proximal thigh (proximal) and ipsilateral
gaiter area (distal) in patient with venous reflux. An
increased amount of fibronectin strands (s ) can be appre-
ciated. With this technique, dermal fibronectin deposition
was found to be increased in the distal dermis of 3 of 6
patients tested with venous reflux.
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ent proliferative stages. Senescent or near senescent
fibroblasts become resistant to mitogenic stimuli by
several growth factors.7,22 Then, the b-FGF–mediat-
ed increment in the overall growth rate is provided
by the proportion of young rapidly proliferating
fibroblasts within a particular cell population. We
can speculate then that fibroblast populations that
are isolated from intact skin subjected to venous
hypertension have a large proportion of young pro-
liferating fibroblasts and this is why stimulation with
b-FGF restored the growth rate to that of stimulat-
ed proximal fibroblasts. We also can speculate that
the proportion of young fibroblasts within the cell
populations that are isolated from the patient with
venous hypertension is greater than that of the
fibroblasts that are isolated from the venous ulcers,
which accounts for the increased responsiveness of
the former.
The location of the biopsy site could be a poten-
tial source of error because, in theory, the distal
fibroblasts have undergone a greater number of cell
divisions during embryologic development than the
proximal fibroblasts. For the subjects with no docu-
mented venous reflux, no differences were noted in
the fibroblast growth rates or the senescence bio-
markers between the proximal and distal fibroblasts.
These findings suggest that the constitutional cell
division difference between the proximal and distal
fibroblasts does not seem to contribute significantly
with the changes observed on the distal fibroblasts
from a patient with venous reflux.
With immunohistochemical analysis, the deposi-
tion of fibronectin within the dermis of the skin sub-
jected to venous hypertension was found to be
increased in half of the patients studied when com-
pared with the normal skin of the same patients.
Final dermal fibronectin deposition and stabilization
is a complex process that involves a balance between
the fibronectin generated by the fibroblasts, the
breakdown of fibronectin by proteases, and the
extravasation of plasma fibronectin. When the fluo-
rescent intensities that were measured from each
specimen were compared, statistical significance was
not reached, which was probably as a result of the
small number of patients who were tested. Still, this
method should be considered in the future as a
potential biomarker for the in vivo determination of
senescence characteristics and could be used as a
clinical tool to identify the patients with venous
reflux who are at risk for the development of venous
ulcers or to predict the outcome of chronic ulcers.
The mechanisms through which venous hyper-
tension, over time, causes dermal fibroblast senes-
cence are not known. We can only speculate that
venous hypertension, through the establishment of
an inflammatory environment, may chronically stim-
ulate dermal fibroblast proliferation, which exhausts
their replicative lifespan by shortening the telomere
length. It is also possible that mediators that are
released locally in this inflammatory environment act
as noxious stimuli for susceptible young rapidly
replicating fibroblasts, which select out for more sta-
ble and resistant “old” cells. It is likely that perivas-
cular fibrin cuffing, white blood cell trapping and
activation, and growth factor imbalances all play
some role in the selection or accumulation of aged
fibroblasts.
The accumulation in vivo of senescent fibroblasts
over time is possible because they become resistant
to apoptosis on senescence.23 Also, they are unable
to proliferate as well as normal fibroblasts,22 are less
motile,22 and produce a different array of proteins,
which includes elevated levels of matrix metallopro-
teinases6 and proinflammatory cytokines7 that can
affect tissue integrity and normal healing. This is a
novel pathophysiologic concept that may explain
some of the cellular mechanisms of disease involved
in venous ulcer formation and chronic venous insuf-
ficiency.
Some potential different therapeutic approaches
can be derived from these findings. Bypass of
replicative senescence has been achieved in the labo-
ratory through different mechanisms,21,24 and this
technology could have therapeutic implications in
the future management of venous ulcers and chron-
ic venous insufficiency.
Table V. Fibroblast growth rates in patients without venous reflux (n = 4)
Growth rates (cells/day) P value
Fibroblast population No b-FGF b-FGF (100 ng/mL)
Proximal fibroblasts 30,339 ± 9191 52,421 ± 15,746 .27
Distal fibroblasts 32,956 ± 10,724 62,964 ± 25,333 .22
P value .69 .44
b-FGF, Basic fibroblast growth factor.
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CONCLUSION
We conclude that the fibroblasts that were isolat-
ed from the intact skin subjected to venous hyper-
tension exhibited more characteristics of senescence
when compared with the fibroblasts that were isolat-
ed from the unaffected skin of the same patient. This
implies that (1) fibroblasts abnormalities exist before
the development of venous ulcers in patients with
venous reflux and (2) the local accumulation of
senescent fibroblasts in dermis subjected to venous
hypertension or venous ulcers is a result of intrinsic
mechanism directly related to venous hypertension
itself and not to extrinsic mechanisms, such as injury
or infection. b-FGF restores fibroblast proliferation
in vitro, which suggests a potential therapeutic role.
The immunohistochemical determination of dermal
fibronectin deposition could be a clinically applica-
ble tool to assess senescence characteristics in vivo.
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Dr Peter J. Pappas (Newark, NJ). Dr Mendez and his
colleagues at Boston University are to be congratulated on
developing an in vitro model to try and determine some of
the pathophysiologic mechanisms associated with chronic
venous insufficiency. In the current study, fibroblasts were
isolated from the gaiter and ipsilateral thigh skin biopsies in
DISCUSSION
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9 patients in class 4, in 3 patients in class 5, and in 4 nor-
mal controls. The fibroblast cultures then were analyzed
for growth rate response to basic fibroblast growth factor,
fibronectin protein production, and the presence of senes-
cence-associated b -galactosidase staining, a marker of
senescence. The authors noted that the growth rates for
unstimulated chronic venous insufficiency fibroblasts
showed decreased growth but were able to proliferate like
normal cells when stimulated with basic fibroblast growth
factor. They also noted no differences in the growth rates
between the stimulated and nonstimulated cells that were
obtained from the normal controls. Similarly, they noted a
higher percentage of senescence-associated b -galactosidase
cells in the gaiter biopsies of patients with chronic venous
insufficiency as compared with ipsilateral biopsies and biop-
sies obtained from the normal controls.
I have several questions for the authors.
1. Could you please elaborate for me exactly what the
term senescence means? I know you touched on
this in your presentation. However, to me, senes-
cence, or aging, implies an inability to respond to
stimuli as a result of the aging process. In your ear-
lier publication, you mentioned that the cells
appeared burned out. Could you please clarify
exactly what a senescent cell cannot do functionally
that a young cell can do and what the significance is
of fibronectin in determining senescence?
2. The second question regards your study design. In
your study, you mentioned that 2 of the normal con-
trols were patients who had chronic venous insuffi-
ciency with no evidence of reflux. Could you elabo-
rate on the extent of their venous disease, and do
you think these patients are truly normal controls?
3. Did you compare the growth rates of the distal
fibroblasts from patients with chronic venous insuf-
ficiency and from normal controls? It appears that
you only compared the growth rates of the distal
and proximal fibroblasts within the same group. To
my inspection, the growth rates of the patients with
chronic venous insufficiency and of the normal con-
trols looked different.
4. These data obviously conflict with your earlier pub-
lication that showed diminished proliferative growth
rates in biopsies obtained from patients with active
ulcers. In that earlier publication, cells stimulated
with growth factors could not even reach prolifera-
tive rates of nonstimulated normal controls. In the
present study, this phenomenon is reversed. You
mentioned in your presentation that this could be a
result of a higher proportion of younger fibroblasts
in the cultures that were not senescent. In fact,
91.7% of your cells were senescence-associated b -
galactosidase negative, and the majority of your
patients were class 4, as opposed to your previous
study in which the majority of your patients were
patients with active ulcers.
You also mentioned that the cytochemical environ-
ment could affect your results. We at the New Jersey
Medical School would agree with your latter supposition.
An electron photomicrograph taken from some of our
patients shows an intense inflammatory response. You can
see this in a postcapillary venule, with pericapillary cuffing,
macrophages that are migrating into lymphatic channels,
and the presence of mast cells and macrophages in close
apposition to fibroblasts.
To determine what is going on in the cytochemical
environment, we performed immunohistochemistry and
looked for TGF- b –1, and we found that TGF- b -1 was
present in the epidermis, in the pericapillary cuffing, and
in leukocytes. So, we believe that the cytochemical envi-
ronment that these cells are exposed to is probably one of
the more major reasons for some of the events that are
occurring at the cellular level.
In light of these facts, do you think it would be valu-
able to stratify your patients according to the clincal, etio-
logic, anatomic, and pathologic classification and reana-
lyze your data to see if these altered proliferation rates are
really a function of chronic venous insufficiency? Similarly,
do you think pretreating your fibroblasts with TGF-b and
then applying your growth factors would be valuable in
determining the mechanisms associated with diminished
growth responses?
I greatly enjoyed your study, and I applaud the Boston
University group for their interesting and necessary work
on fibroblast physiology in patients with venous insuffi-
ciency. Thank you very much.
Dr Manuel V. Mendez. Thank you, Dr Pappas, for
your comments and questions.
First, I want to expand on the concept of senescence.
Except for a few cells types, there is a limited replicative
life span for all human cells. A senescent stage is reached
after a certain amount of population doublings. For
fibroblasts, particularly, it is somewhere around 70 to 80
cumulative cell divisions.
In the process of reaching senescence in vitro, there is
going to be a heterogeneous group of fibroblasts. There is
going to be a proportion of cells that have undergone only
a few divisions—young, rapidly replicating cells that usual-
ly respond well to growth factors. There is going to be a
proportion of cells that have reached senescence that are
unable to divide anymore. At this stage, they cannot repli-
cate their DNA despite stimulation by growth factors. In
between, there is going to be a group of cells that have
undergone a certain number of population doublings and
are near the stage of senescence.
Once the cells get to the senescent stage, as I men-
tioned before, they acquire altered cell functions. There
have been over 200 described altered cell functions acquired
by senescent cells, some of which I alluded in my presenta-
tion, like increase in fibronectin production, increase in col-
lagenase activity, and decrease in the expression of TIMPs.
Fibronectin is one of the classically described altered cell
functions that have been demonstrated and used as a bio-
marker for the study of senescence in vitro. Interestingly,
fibronectin is part of the chemical composition of the fibrin
cuff that was actually shown in your slide. Also, fibronectin
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fragments, when broken down by collagenases or proteases,
are chemoattractants to macrophages and actually can acti-
vate macrophages. So, you can speculate that an increased
production of fibronectin by senescent fibroblasts within
the skin of patients with venous hypertension may in part
explain why we see leukocyte trapping and maybe activation
within these tissues.
In terms of choosing our normal controls, we decided
to compare distal fibroblasts versus proximal fibroblasts
within the same patients because we thought that the only
real difference between the two cell populations was that
the distal fibroblast skin had been subjected to venous
hypertension. I would not call those patients a “normal”
control because, again, these patients do have a chronic
venous insufficiency. However, we thought that this
choice represented the best way to compare these cell pop-
ulations. We did not compare fibroblasts between patients
because we found that there was a lot of variability in the
growth rates between patients.
In terms of growth factor effects, we think that in
fibroblast populations isolated from ulcers, the proportion
of younger cells is smaller when compared with those
patients who do not have an ulcer but do have some
venous hypertension. I think that as time goes by and
venous reflux worsens with the eventual development of
an ulcer, young fibroblasts are pushed to divide and
become closer to senescence. When we talked about an 8%
senescence-associated b -galactosidase positive cell, we
were talking about the population of those fibroblasts that
actually reached senescence in vitro. We were not account-
ing for the proportion of fibroblasts that are on their way
to senescence and may not respond well to basic fibroblast
growth factor. The fact that we are seeing a complete
response to basic fibroblast growth factor in the venous
hypertension patients is probably because that proportion
of cells that are closer to senescence is less than the ones
obtained from the ulcers.
The question about TGF-b is an interesting one. We
are currently looking at the effects of several proinflam-
matory cytokines, like interleukin-1, tumor necrosis fac-
tor, and TGF- b , on the function of neonatal foreskin
fibroblasts. We have found that the addition of TGF-b
actually shows some reduction in the proliferation rate of
these neonatal fibroblasts. If you review the literature,
TGF-b –1 can have either stimulatory effects or inhibitory
effects on the proliferative capacity, depending on the con-
centration used for tissue culture. I do not know whether
the addition of TGF- b to our cells would modify the
response to basic fibroblast growth factor.
In terms of stratifying the data, unfortunately, we did
not have a large enough group of patients to stratify and
analyze the data on the basis of the classification used in
the clinical, etiologic, anatomic, pathologic system.
Dr Robert E. Madden (Valhalla, NY). I was just won-
dering if you have looked at or you plan to do any look-
ing for telomerase activity in your tissue cultures?
Dr Mendez. Recently, interesting experiments have
shown that the length of the telomeric DNA acts as the
“mitotic clock” that limits replicative capacity. Every time
a cell divides, the telomere length shortens. And it gets to
a point that beyond a certain length the cells would not
undergo replication again. We have thought about mea-
suring telomere length of proximal and distal fibroblasts.
Telomerase has been successfully transferred in normal
cells to prolong or lengthen the telomere to overcome
senescence.
Frank T. Padberg, Jr (Boston, Mass). I have a plea
regarding terminology. You used the terms chronic venous
insufficiency, venous hypertension, and reflux inter-
changeably, but you have measured reflux. You imply that
reflux leads to venous hypertension; however, other mea-
surements (residual volume function, or RUF) available
through your testing apparatus, air plethysmography, cor-
relate more closely with venous hypertension as deter-
mined by venous pressure studies. Could you comment on
that, please?
Dr Mendez. We use air plethysmography as our prima-
ry inclusion criteria for the patients. We chose a venous
filling index of greater than 2 mL/s to define venous
hypertension. We also used duplex scan examination to
look at the deep, superficial, and perforated system to cor-
roborate or to confirm the presence of venous reflux.
Dr Anton N. Sidawy (Boston, Mass). When you used
a basic fibroblast growth factor, did you use it on the
senescent cells and the nonsenescent cells? And if you did,
was there a difference in the nonsenescent cells before and
after basic fibroblast growth factor treatment?
Dr Mendez. We did use basic fibroblast growth factor
on all fibroblast populations. Again, the fibroblast popula-
tion in vitro is a heterogenous group of fibroblasts. You
are going to find senescent and nonsenescent cells. We
looked at the growth rates without basic fibroblast growth
factor, which is when we saw that there was a significant
difference between the proximal and distal fibroblasts
(30,000 cells/day vs 15,000 cells/day). When we added
basic fibroblast growth factor, we first observed a signifi-
cant increase in the growth rates of both proximal and dis-
tal fibroblasts.
It appeared that the response of the distal fibroblast
was higher than the response of the proximal fibroblast.
But on statistical analysis, there was no significant differ-
ence. We found that adding basic fibroblast growth factor
brought up the growth rate of the distal fibroblasts to that
of stimulated proximal fibroblasts. The increment in
growth rate is a result of the response to basic fibroblast
growth factor by the proportion of young fibroblasts with-
in these cell populations.
Dr Sidawy. Did you do the significance on the effect of
no basic fibroblast growth factor and the basic fibroblast
growth factor on the proximal cells?
Dr Mendez. Yes. When we looked at these 2 cells and
compared, there was a significant response to basic fibro-
blast growth factor. And again, it was significant in the dis-
tal fibroblasts. When we looked at the difference between
the 2 of them with basic fibroblast growth factor, there
was no significant difference.
